SAS and Carolina partner to accelerate antiviral drug development

Posted Nov 19, 2021
SAS, a leader in analytics and software services, and the University of North Carolina are teaming up to transform the drug development process to prevent infectious disease threats from turning into a pandemic like COVID-19. The partnership is focused on the work of the University’s Rapidly Emerging Antiviral Drug Development Initiative (READDI). (UNC.edu)

Related: Campus Connections

Coker Arboretum provides tranquility, history
At the intersection of East Cameron Avenue and Raleigh Street lies the Coker Arboretum, a lush green escape from the rest of UNC’s bustling campus...
Thu Jul 10, 2025

UNC ranked No. 3 best value public university by Princeton Review
UNC-Chapel Hill is ranked the No. 3 best value public university in the nation in The Princeton Review’s list of Best Value Colleges for 2025,...
Wed Jul 9, 2025

Orange County Hit Hard by Tropical Storm Chantal
More than 10 inches of rain fell in a matter of hours and rivers and creeks surged. In Chapel Hill, Morgan Creek exceeded flood stage...
Tue Jul 8, 2025

UNC opens new Down syndrome clinic, serves patients of all ages
For UNC pediatrician Dr. Kate Westmoreland, one of the hardest years of her life came after the birth of her daughter Izabel, who was born...
Sat Jul 5, 2025